Literature DB >> 25243942

Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.

Chae Jin Jeong1, Ho Yun Lee, Joungho Han, Ji Yun Jeong, Kyung Soo Lee, Yoon-La Choi, Joon Young Choi.   

Abstract

OBJECTIVES: For the ultimately efficient screening of anaplastic lymphoma kinase gene (ALK)-positive cases, combination of radiometabolic characteristics with clinicopathologic features may be more useful. Therefore, we determined radiologic characteristics and metabolic characteristics in patients with adenocarcinoma harboring ALK mutations. PATIENTS AND METHODS: We retrospectively reviewed clinicopathologic CT and PET/CT data from patients with advanced lung adenocarcinoma screened for identifying ALK rearrangement. Lesion size, solidity, location, margins, CT attenuation, and SUVmax were assessed. Pathologic features such as differentiation, the presence of signet ring cell, EGFR/KRAS mutation status, and TTF-1 expression were also reviewed.
RESULTS: Of the screened 221 patients, 41 patients (19%) demonstrated ALK rearrangements, and these individuals were younger than the ALK-negative patients (P < 0.001) and showed significant association with no exposure to tobacco (P = 0.028). ALK-positive lung adenocarcinomas were significantly less differentiated than those without rearrangements (P = 0.005). ALK-positive tumors showed significantly higher SUVmax than ALK-negative tumors (P = 0.016). Multivariate logistic regression modeling for predicting the ALK-positive lung adenocarcinoma disclosed that lower CT attenuation and higher SUVmax were significant independent factors of ALK rearrangements (odds ratio, 0.87 and 1.06; P = 0.03 and 0.01, respectively). Receiver operating characteristic analysis showed that the area under the receiver operating characteristic curve for SUVmax/CT attenuation ratio was 0.788, and the optimal cutoff value of SUVmax/CT attenuation ratio for identifying ALK-positive lung adenocarcinoma was greater than or equal to 0.208 (sensitivity, 74.2%; specificity, 81.0%).
CONCLUSIONS: This study shows that ALK-rearranged lung adenocarcinoma represents younger age, no history of smoking, the absence of spiculation on CT, and higher SUVmax/CT attenuation greater than or equal to 0.208 compared with those without ALK mutation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25243942     DOI: 10.1097/RLU.0000000000000581

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

1.  CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Soon Ho Yoon; Darragh F Halpenny; Sangwon Han; Chong Hyun Suh
Journal:  AJR Am J Roentgenol       Date:  2019-08-15       Impact factor: 3.959

Review 2.  CT Radiomics in Thoracic Oncology: Technique and Clinical Applications.

Authors:  Geewon Lee; So Hyeon Bak; Ho Yun Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-12-18

3.  Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.

Authors:  Maomei Ruan; Liu Liu; Lihua Wang; Bei Lei; Xiaoyan Sun; Cheng Chang; Yan Shen; Wenhui Xie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-03       Impact factor: 9.236

4.  Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.

Authors:  Zhilei Lv; Jinshuo Fan; Juanjuan Xu; Feng Wu; Qi Huang; Mengfei Guo; Tingting Liao; Shuqing Liu; Xiaoli Lan; Shanshan Liao; Wei Geng; Yang Jin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

5.  18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma.

Authors:  Yanping Jiang; Lijuan Wang; Wenlan Zhou; Jiamei Gu; Ying Tian; Ye Dong; Lilan Fu; Hu-Bing Wu
Journal:  Cancer Imaging       Date:  2020-01-10       Impact factor: 3.909

6.  Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

Authors:  Ki Hwan Kim; Jinho Kim; Hyunjin Park; Hankyul Kim; Seung-Hak Lee; Insuk Sohn; Ho Yun Lee; Woong-Yang Park
Journal:  Thorac Cancer       Date:  2020-07-22       Impact factor: 3.500

7.  Study on the Correlation Between CT Features and Vascular Tumor Thrombus Together With Nerve Invasion in Surgically Resected Lung Adenocarcinoma.

Authors:  Yu Song; Daiwen Chen; Duohuang Lian; Shangwen Xu; Hui Xiao
Journal:  Front Surg       Date:  2022-06-28

8.  Alternative and New Radiopharmaceutical Agents for Lung Cancer.

Authors:  Silvi Telo; Letizia Calderoni; Sara Vichi; Federico Zagni; Paolo Castellucci; Stefano Fanti
Journal:  Curr Radiopharm       Date:  2020

9.  Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients.

Authors:  Lan Song; Zhenchen Zhu; Li Mao; Xiuli Li; Wei Han; Huayang Du; Huanwen Wu; Wei Song; Zhengyu Jin
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.